Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Wednesday 09 November, 2016

AstraZeneca PLC

Directorate Change

RNS Number : 6332O
AstraZeneca PLC
09 November 2016

9 November 2016 07:00





AstraZeneca today announced that Jean-Philippe Courtois, a Non-Executive Director, will step down from the Board of AstraZeneca PLC and as a member of the Company's Audit Committee with effect from 1 December 2016.


Mr Courtois was appointed as a Non-Executive Director of AstraZeneca in 2008.  The Board's Nomination and Governance Committee started succession planning work in February this year, in anticipation of him reaching nine years' tenure in 2017.  Mr Courtois has recently taken on new responsibilities as Executive Vice President and President, Microsoft Global Sales, Marketing and Operations.


Leif Johansson, AstraZeneca Chairman, said:  "On behalf of the Board, I would like to express my gratitude for Jean-Philippe's contribution to our work and that of the Audit Committee.  I speak for all my colleagues in saying that we will miss his business acumen, extensive experience of the global technology industry, common sense and collegiality.  We wish him all the best for his future endeavours."



About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca.



Media Enquiries






Neil Burrows




+44 203 749 5637


Vanessa Rhodes




+44 203 749 5736


Karen Birmingham




+44 203 749 5634


Rob Skelding




+44 203 749 5821


Jacob Lund




+46 8 553 260 20


Michele Meixell




+1 302 885 2677


Investor Relations

Thomas Kudsk Larsen




+44 203 749 5712


Craig Marks


Finance, Fixed Income, M&A


+44 7881 615 764


Henry Wheeler




+44 203 749 5797


Mitchell Chan




+1 240 477 3771


Lindsey Trickett


Cardiovascular & Metabolic Diseases


+1 240 543 7970


Nick Stone




+44 203 749 5716


Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US toll free

+1 866 381 7277


Adrian Kemp

Company Secretary, AstraZeneca PLC






This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t